1. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
   Daniel Morales-Cano et al, 2023, Frontiers in Pharmacology CrossRef
2. Therapeutic effects of conditioned medium from bone marrow-derived mesenchymal stem cells on epithelial-mesenchymal transition in A549 cells
   Xin Wang et al, 2017, International Journal of Molecular Medicine CrossRef
3. TAK1 blockade as a therapy for retinal neovascularization
   Jiang-Hui Wang et al, 2023, Pharmacological Research CrossRef
4. LYTAK1 attenuates proliferation of retinal pigment epithelial cells through TGF‑β‑mediated epithelial‑mesenchymal transition via the ERK/AKT signaling pathway
   Zhen Chen et al, 2017, Experimental and Therapeutic Medicine CrossRef
5. Polarity and epithelial-mesenchymal transition of retinal pigment epithelial cells in proliferative vitreoretinopathy
   Hui Zou et al, 2020, PeerJ CrossRef
6. TAK1 signaling is a potential therapeutic target for pathological angiogenesis
   Linxin Zhu et al, 2021, Angiogenesis CrossRef
7. TAK -ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy
   Raffaela Santoro et al, 2017, Drug Resistance Updates CrossRef